The primary focus has been on the presence of elevated asprosin and implications for the pathology of metabolic syndrome (reviewed by Summers et al. 2023), but models of asprosin deficiency may also be beneficial to human patients who lack the ability to make asprosin because of a genetic variant. This evidence concerns the gene FBN1 and hyperinsulinemic hypoglycemia, familial, 4.